Chiusura precedente | 214,55 |
Aperto | 212,30 |
Denaro | 211,20 x N/D |
Lettera | 222,00 x N/D |
Min-Max giorno | 212,30 - 218,40 |
Intervallo di 52 settimane | 212,30 - 298,40 |
Volume | |
Media Volume | 916.406 |
Capitalizzazione | 183,8B |
Beta (5 anni mensile) | 0,18 |
Rapporto PE (ttm) | 16,66 |
EPS (ttm) | 13,00 |
Prossima data utili | 25 lug 2024 |
Rendimento e dividendo (futuro) | 9,50 (3,99%) |
Data ex dividendo | 16 mar 2023 |
Stima target 1A | N/D |
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS) More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeks The safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to date B
10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS contr
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutane